Evidence map›Paper›PMID 25135832›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2014

Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry.

Qingsheng Li, Ming Zeng, Lijie Duan, James E Voss, Anthony J Smith, Stefan Pambuccian, Liang Shang, Stephen Wietgrefe, Peter J Southern, Cavan S Reilly and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Resident Memory B Cells in Barrier Tissues.Frontiers in immunology · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Qingsheng LiDepartment of Microbiology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Ming ZengDepartment of Microbiology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Lijie DuanDepartment of Microbiology, Medical School, University of Minnesota, Minneapolis, MN 55455;
James E VossDepartment of Immunology and Microbial Science, International AIDS Vaccine Initiative Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Design, The Scripps Research Institute, La Jolla, CA 92037; Ragon Institute of MGH, MIT, and Harvard, Charlestown, MA 02129;
Anthony J SmithDepartment of Microbiology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Stefan PambuccianDepartment of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Liang ShangDepartment of Microbiology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Stephen WietgrefeDepartment of Microbiology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Peter J SouthernDepartment of Microbiology, Medical School, University of Minnesota, Minneapolis, MN 55455;
Cavan S ReillyDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN 55455;
Pamela J SkinnerDepartment of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108;
Mary L ZupancicDepartment of Microbiology, Medical School, University of Minnesota, Minneapolis, MN 55455;
John V CarlisDepartment of Computer Science and Engineering, College of Science and Engineering, University of Minnesota, Minneapolis, MN 55455;
Michael PiatakAIDS and Cancer Virus Program, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, MD 21702;
Diane WatermanZeptoMetrix Corporation, Buffalo, NY 14202;
R Keith ReevesNew England Primate Research Center, Harvard Medical School, Southborough, MA 01772; Infectious Disease Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02115;
Katherine Masek-HammermanNew England Primate Research Center, Harvard Medical School, Southborough, MA 01772; Infectious Disease Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02115;
Cynthia A DerdeynDepartment of Pathology and Laboratory Medicine and Emory Vaccine Center, Emory University, Yerkes, Atlanta, GA 30329;
Michael D AlpertNew England Primate Research Center, Harvard Medical School, Southborough, MA 01772; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115;
David T EvansNew England Primate Research Center, Harvard Medical School, Southborough, MA 01772; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115;
Heinz KohlerDepartment of Microbiology and Immunology and Molecular Genetics, University of Kentucky, Lexington, KY 40536;
Sybille MüllerImmPheron Inc., Lexington, KY 40509; and.
James RobinsonDepartment of Pediatrics, Center for Infectious Diseases, Tulane University, New Orleans, LA 70112.
Jeffrey D LifsonAIDS and Cancer Virus Program, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, MD 21702;
Dennis R BurtonDepartment of Immunology and Microbial Science, International AIDS Vaccine Initiative Neutralizing Antibody Center, and Center for HIV/AIDS Vaccine Immunology and Immunogen Design, The Scripps Research Institute, La Jolla, CA 92037; Ragon Institute of MGH, MIT, and Harvard, Charlestown, MA 02129;
R Paul JohnsonRagon Institute of MGH, MIT, and Harvard, Charlestown, MA 02129; New England Primate Research Center, Harvard Medical School, Southborough, MA 01772;
Ashley T HaaseDepartment of Microbiology, Medical School, University of Minnesota, Minneapolis, MN 55455; haase001@umn.edu.

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI BHARDWAJ, NINA · 2006 to 2011
$290.5M
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
ZETA CHAIN OF T CELL RECEPTOR INTERACTS W/ NEF OF SIV &HIV2P51RR000168 · NCRR · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WESTMORELAND, SUSAN V. · 1985 to 2011
$139.3M
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
VirologyU19AI095985 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2011 to 2015
$35.9M
Pathology and Veterinary Service CoreP01AI071306 · NIAID · HARVARD MEDICAL SCHOOL · PI JOHNSON, R. PAUL · 2007 to 2011
$18.3M
Antibody Effector Function in Protection Against HIV-1R37AI055332 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2009 to 2018
$9.7M
Role of V1V2 in HIV transmission and pathogenesisR01AI058706 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DERDEYN, CYNTHIA ANN · 2004 to 2016
$6.7M
ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1R01AI055332 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2003 to 2007
$3.8M
KIR and MHC Class I Immunogenetics in SIV InfectionR01AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.7M
Lentiviral Resistance to TetherinR01AI098485 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.2M
MOUSE MODELS OF CANCER, BONE DISEASE, AND LACTATIONK26RR000168 · NCRR · OHIO STATE UNIVERSITY · PI ROSOL, THOMAS J · 2000 to 2004
$547k
NCI NIH HHS HHSN261200800001ENCRR NIH HHS K26 RR000168NCRR NIH HHS P51 RR000168NCRR NIH HHS RR00168NIAID NIH HHS 1UM1AI100663NIAID NIH HHS AI 055332NIAID NIH HHS AI 071306NIAID NIH HHS AI 086922NIAID NIH HHS AI095985NIAID NIH HHS HHSN272201100023CNIAID NIH HHS P01 AI071306NIAID NIH HHS R01 AI055332NIAID NIH HHS R01 AI058706NIAID NIH HHS R01 AI098485NIAID NIH HHS R21 AI086922NIAID NIH HHS R37 AI055332NIAID NIH HHS U19 AI 067854NIAID NIH HHS U19 AI067854NIAID NIH HHS U19 AI095985NIAID NIH HHS UM1 AI100663NIH HHS P51 OD011132
6 · The paper itself

Abstract

We sought design principles for a vaccine to prevent HIV transmission to women by identifying correlates of protection conferred by a highly effective live attenuated SIV vaccine in the rhesus macaque animal model. We show that SIVmac239Δnef vaccination recruits plasma cells and induces ectopic lymphoid follicle formation beneath the mucosal epithelium in the rhesus macaque female reproductive tract. The plasma cells and ectopic follicles produce IgG Abs reactive with viral envelope glycoprotein gp41 trimers, and these Abs are concentrated on the path of virus entry by the neonatal FcR in cervical reserve epithelium and in vaginal epithelium. This local Ab production and delivery system correlated spatially and temporally with the maturation of local protection against high-dose pathogenic SIV vaginal challenge. Thus, designing vaccines to elicit production and concentration of Abs at mucosal frontlines could aid in the development of an effective vaccine to protect women against HIV-1.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralAntibody FormationCervix UteriFemaleHIV-1HIV Envelope Protein gp41HIV InfectionsImmunoglobulin GMacaca mulattaMucous MembraneSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVaccinationAntibodies, NeutralizingAntibodies, ViralHIV Envelope Protein gp41Immunoglobulin GSAIDS VaccinesVaccines, Attenuated

Identifiers

PMID25135832
PMCPMC4157131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.